Abstract
The interpretation of studies of decline of FEV1 in patients with established COPD is complicated by many methodologic problems, such as retrospective analyses, small patient groups, different patient selection, and differences in the mathematical models used. Nevertheless, it is clear that the rate of loss of lung function is above all determined by the smoking status and history. A more abnormal bronchoconstrictor response is predictive of a steeper decline of lung function. Other prognostic factors have not been consistently found in patients with established disease. The decline can be influenced favorably by smoking cessation, and probably by oxygen administration in hypoxemic patients. Long-term oral steroid use seems to be associated with a more favorable course of FEV1, but the value of inhaled corticosteroids has not yet been established. Maintenance therapy with bronchodilators only does not appear to improve the decline of FEV1.
References
Nov 12, 1992·The New England Journal of Medicine·H A KerstjensH J Mengelers
Jun 1, 1992·Thorax·P L BrandH J Sluiter
Jul 1, 1991·The American Review of Respiratory Disease·D L SherrillB Burrows
Jul 1, 1989·The American Review of Respiratory Disease·G RaghuA S Narayanan
Sep 1, 1989·The American Review of Respiratory Disease·D S Postma, H J Sluiter
Jan 1, 1986·The American Review of Respiratory Disease·N R AnthonisenJ E Hodgkin
Apr 1, 1987·The American Review of Respiratory Disease·B BurrowsM D Lebowitz
Jul 1, 1987·The American Review of Respiratory Disease
Oct 1, 1985·Thorax·A H CampbellR Huggins
Nov 1, 1983·Annals of Internal Medicine
Sep 1, 1980·Annals of Internal Medicine
Jan 1, 1995·American Journal of Respiratory and Critical Care Medicine·X Xu, B Li
Nov 1, 1994·American Journal of Respiratory and Critical Care Medicine·P LeuenbergerM Brutsche
Mar 1, 1993·The American Review of Respiratory Disease·K Ström
May 15, 1993·Annals of Internal Medicine·E DompelingC van Weel
Citations
Feb 27, 2009·Medizinische Klinik·Adrian GillissenRoland Buhl
Jan 19, 2005·Der Internist·H R Wirtz
Jan 3, 2001·The New England Journal of Medicine·UNKNOWN Lung Health Study Research GroupMelissa Skeans
Sep 2, 1998·Proceedings of the National Academy of Sciences of the United States of America·S J GangeJ B Margolick
Apr 2, 2011·High Altitude Medicine & Biology·Denis VinnikovRupert Redding-Jones
Dec 12, 2002·Current Opinion in Pulmonary Medicine·Nick H T Ten HackenWim Timens
Aug 24, 1999·BMJ : British Medical Journal·H A Kerstjens
Aug 1, 2002·Thorax·G T VerhoevenJ-B Prins
Jul 30, 2003·Thorax·P M A CalverleyP W Jones
Mar 16, 2006·Thorax·D G ParrR A Stockley
Nov 26, 1997·Thorax·H A KerstjensD S Postma
Feb 24, 2001·American Journal of Respiratory and Critical Care Medicine·K A GriffithP L Enright
Apr 9, 2004·American Journal of Respiratory and Critical Care Medicine·Susheel P PatilAlan R Schwartz
Feb 25, 2011·BMC Health Services Research·Douglas W MapelBarry Make
Dec 16, 2010·BMC Medicine·Peter N Lee, John S Fry
Dec 21, 2006·COPD·Sunghye KimCarlos A Camargo
Sep 18, 2009·Current Medical Research and Opinion·Barbara YawnGlenn Crater
Aug 9, 2003·Chest·Karin H GroenewegenEmiel F M Wouters
Apr 18, 2000·Chest·G T FergusonM W Higgins
Jan 14, 2009·Journal of Clinical Pharmacy and Therapeutics·T GuranE Dagli
Feb 24, 2001·Clinics in Chest Medicine·P L Enright, R O Crapo
Aug 21, 2010·Respiratory Medicine·A H MoriceM Decramer
Jul 13, 2001·Pulmonary Pharmacology & Therapeutics·C Owen